ND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Neogi et al. Appln. No.:

10 Series Code 个

075,442 Serial No.

Filed: February 15, 2002 Hon. Commissioner of Patents Washington, D.C. 20231

Group Art Un Examiner: Atty. Dkt.

1625

Hector M. Reyes

0290459 Client Ref M#

Appln. Title: **Novel Compounds to Treat Diabetes** 

and Associated Conditions

Sir:

## REPLY/AMENDMENT/LETTER

Date: December 24, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim							
A. \( \sum \) NOT made For B & C See Required	Claims Highest number		Present Extra	Large/Small Entity	Additional	Fee Code	
C made herewith Separate Paper	remaining after amendment	previously paid for				Fee	Lg/Sm
D. Made previously (Pat-256)							
					·		
2. Total Effective Claims	15	**minuş	20	0	x \$18/\$9 =	+ \$0	103/203
Independent Claims	14	***minus	14	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u>							
time (leave <u>blank</u> if this is a <u>reissue</u> application)					+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: November 27, 2002 NONE							
6. <b>Petition is hereby made</b> to extend the original due (1 mo)   \$110/\$55 =							115/215
date to cover the date this response is filed for which the (2 mos) \$400/\$200 =   + \$55							116/216 117/217
requisite fee is attached (3 mos)   \$920/\$460 =							118/217
(4 mos)   \$1,440/\$720=							128/228
(5 mos)   \$1,960/\$980=							
7. Enter any previous extension fee paid since above <u>original</u> due date and <u>subtract</u> - \$0							
8. Extension Fee						+ \$55	
9. If <u>Terminal Disclaimer</u> attached, <u>add</u> Rule 20(d) official fee						+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180	+ \$0	126 126
or if Rule 97(d) Request						<u>'</u>	
					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
					+ \$740/370	+ \$0	1179/1279
14. Petition fee for						+ \$0	
15. TOTAL FEE =						\$55	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						PLEASE CHARGE	
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.  18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						DEPOSIT A	CCOUNT
CHARGE Deposit Account No. 03-3975							

Our Order No. 007426 0290459 M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Sig:

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group

P.O. Box 10500 McLean, VA 22102 Tel: (703) 905-2000

Paul L. Sharer By Atty:

Reg. No. 36,004

Fax:

(703) 905-2500

Tel: (703) 905-2180

tty/Sec: PLS/kmh

OTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

Application Serial No. 10/075,442

Confirmation No. 1127

communation No. 1127

Group Art Unit: 1625

Examiner: Hector M. Reyes

Filed: February 15, 2002

Neogi et al.

For: NOVEL COMPOUNDS TO TREAT DIABETES AND ASSOCIATED CONDITIONS

December 24, 2002

## **AMENDMENT**

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the Official Action dated August 27, 2002, please enter the following amendments and consider the remarks made herein.

## IN THE CLAIMS

Please amend the following claims:

25. (Twice Amended) A compound of the formula II:

W T

wherein stereocenters \* are R or S;

(2/27/2002 MADDELR1 00000119 033975 10075442